 Boston Scientific Corp.s BSX, 0.88 615 million acquisition of Apollo Endosurgery Inc. APEN, 65.50 announced earlier is complementary to the formers endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientifics 2023 per-share earnings but to boost it after that. 